BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152:706-715. [PMID: 28257716 DOI: 10.1053/j.gastro.2017.01.031] [Cited by in Crossref: 322] [Cited by in F6Publishing: 270] [Article Influence: 64.4] [Reference Citation Analysis]
Number Citing Articles
1 Pironi L, Raschi E, Sasdelli AS. The safety of available treatment options for short bowel syndrome and unmet needs. Expert Opin Drug Saf 2021;:1-13. [PMID: 34105428 DOI: 10.1080/14740338.2021.1940947] [Reference Citation Analysis]
2 Stein E, Sloan J, Sonu I, Kathpalia P, Jodorkovsky D. GERD for the nongastroenterologist: successful evaluation, management, and lifestyle-based symptom control. Ann N Y Acad Sci 2020;1482:106-12. [PMID: 32944973 DOI: 10.1111/nyas.14496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investig Otolaryngol 2018;3:457-62. [PMID: 30599030 DOI: 10.1002/lio2.187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Zhang M, Hou ZK, Huang ZB, Chen XL, Liu FB. Dietary and Lifestyle Factors Related to Gastroesophageal Reflux Disease: A Systematic Review. Ther Clin Risk Manag 2021;17:305-23. [PMID: 33883899 DOI: 10.2147/TCRM.S296680] [Reference Citation Analysis]
5 Kinoshita Y, Ishimura N, Ishihara S. Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors? American Journal of Gastroenterology 2018;113:1417-9. [DOI: 10.1038/s41395-018-0183-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Kliewer KL, Cassin AM, Venter C. Dietary Therapy for Eosinophilic Esophagitis: Elimination and Reintroduction. Clinic Rev Allerg Immunol 2018;55:70-87. [DOI: 10.1007/s12016-017-8660-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
7 Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". Dig Liver Dis 2018;50:894-902. [PMID: 30093304 DOI: 10.1016/j.dld.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
8 Triantafylidis LK, Hawley CE, Perry LP, Paik JM. The Role of Deprescribing in Older Adults with Chronic Kidney Disease. Drugs Aging 2018;35:973-84. [PMID: 30284120 DOI: 10.1007/s40266-018-0593-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
9 Blackett JW, Faye AS, Phipps M, Li J, Lebwohl B, Freedberg DE. Prevalence and Risk Factors for Inappropriate Continuation of Proton Pump Inhibitors After Discharge From the Intensive Care Unit. Mayo Clin Proc 2021;96:2550-60. [PMID: 33308869 DOI: 10.1016/j.mayocp.2020.07.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Luu AM, Vogel SR, Braumann C, Praktiknjo M, Höhn P, Förster S, Janot M, Uhl W, Belyaev O. Risk factors for perforated marginal ulcers following pancreaticoduodenectomy and prospective analysis of marginal ulcer development. Gland Surg 2021;10:739-50. [PMID: 33708556 DOI: 10.21037/gs-20-763] [Reference Citation Analysis]
11 Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, Sheu BS, Chong CF, Funao N, Zhou W, Chen M. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 2020;69:224-30. [PMID: 31409606 DOI: 10.1136/gutjnl-2019-318365] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
12 Smukalla SM, Dimitrova I, Feintuch JM, Khan A. Dysphagia in the Elderly. Curr Treat Options Gastroenterol 2017;15:382-96. [PMID: 28756531 DOI: 10.1007/s11938-017-0144-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
13 Vinke P, Wesselink E, van Orten-Luiten W, van Norren K. The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses. Int J Mol Sci 2020;21:E323. [PMID: 31947724 DOI: 10.3390/ijms21010323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776. [PMID: 29383028 DOI: 10.1177/1756283x17745776] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
15 Monteiro RLR, Kobayasi MAMR, Araujo MR, Monteiro DR, Andreollo NA. Omeprazole and adenocarcinoma in the stomach of rats submitted to duodenogastric reflux. Is there a protective effect? Acta Cir Bras 2020;35:e202000904. [PMID: 33027361 DOI: 10.1590/s0102-865020200090000004] [Reference Citation Analysis]
16 Lin D, Eke C, Cai C, Thrift AP, Shukla R. Decreasing Overall and Inappropriate Proton Pump Inhibitor Use: Perspective From a Large Safety-Net Healthcare System. Clinical Gastroenterology and Hepatology 2020;18:763-766.e2. [DOI: 10.1016/j.cgh.2019.12.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Zhang J, Che H, Zhang B, Zhang C, Zhou B, Ji H, Xie J, Shi X, Li X, Wang F, Tang X. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study. Phytomedicine 2021;88:153584. [PMID: 34119741 DOI: 10.1016/j.phymed.2021.153584] [Reference Citation Analysis]
18 Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf 2019;10:2042098618809927. [PMID: 31019676 DOI: 10.1177/2042098618809927] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
19 Liu J, Lin H, Yuan L, Wang D, Wang C, Sun J, Zhang C, Chen J, Li H, Jing S. Protective Effects of Anwulignan against HCl/Ethanol-Induced Acute Gastric Ulcer in Mice. Evid Based Complement Alternat Med 2021;2021:9998982. [PMID: 34335857 DOI: 10.1155/2021/9998982] [Reference Citation Analysis]
20 Hendrix I, Page AT, Korhonen MJ, Bell JS, Tan ECK, Visvanathan R, Cooper T, Robson L, Sluggett JK. Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services. Drugs Real World Outcomes 2019;6:105-13. [PMID: 31264165 DOI: 10.1007/s40801-019-0157-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Peng CC, Tu YK, Lee GY, Chang RH, Huang Y, Bukhari K, Tsai YC, Fu Y, Huang HK, Munir KM. Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2021:dgab353. [PMID: 34170301 DOI: 10.1210/clinem/dgab353] [Reference Citation Analysis]
22 Saiz Ladera GM, Pejenaute Labari ME, García Pascual JN. [Updating in prescription of proton pump inhibitors. What to do and what not to do]. Semergen 2021;47:267-79. [PMID: 33223372 DOI: 10.1016/j.semerg.2020.09.011] [Reference Citation Analysis]
23 Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. Drug Des Devel Ther 2021;15:1609-21. [PMID: 33907381 DOI: 10.2147/DDDT.S306371] [Reference Citation Analysis]
24 Beinvogl B, Cohen A, DiFilippo C, Kane M, Nurko S, Rosen R. IMPACT OF CORONAVIRUS DISEASE 2019 on THE PEDIATRIC AERODIGESTIVE POPULATION. J Pediatr 2021:S0022-3476(21)01228-2. [PMID: 34942183 DOI: 10.1016/j.jpeds.2021.12.022] [Reference Citation Analysis]
25 Dupont HL. Gastric Acid and Enteric Infections: Souring on the Use of PPIs. Dig Dis Sci 2018;63:814-7. [DOI: 10.1007/s10620-018-4955-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
26 Bang UC, Watanabe T, Bendtsen F. The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis. Eur J Gastroenterol Hepatol. 2018;30:346-351. [PMID: 29309396 DOI: 10.1097/meg.0000000000001060] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
27 Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci 2019;20:E5469. [PMID: 31684070 DOI: 10.3390/ijms20215469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 Hoefsloot S, Urbanski G, Lacout C, Bouvard B, Lavigne C. [Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations]. Rev Med Interne 2021;42:616-24. [PMID: 34148673 DOI: 10.1016/j.revmed.2021.03.326] [Reference Citation Analysis]
29 Hoshikawa Y, Nikaki K, Sonmez S, Nakagawa K, Yazaki E, Sifrim D, Woodland P. Exacerbation of gastroesophageal reflux symptoms after discontinuation of proton pump inhibitors is not associated with increased esophageal acid exposure. Neurogastroenterol Motil 2020;32:e13735. [PMID: 31657519 DOI: 10.1111/nmo.13735] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc 2019;82:756-61. [PMID: 31335628 DOI: 10.1097/JCMA.0000000000000157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Husain NS, El-Serag HB. Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin. Nat Rev Clin Oncol 2018;15:728-30. [PMID: 30237519 DOI: 10.1038/s41571-018-0096-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Sugiyama T. Understanding the Current Evidence on Proton Pump Inhibitor Use and Bone Health. Gastroenterology 2019;157:585. [DOI: 10.1053/j.gastro.2019.04.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, Lee JH, Yang HJ, Cho YK, Bang CS, Kim BJ, Jung HK, Kim BW, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Clinical Guidelines for Drug-induced Peptic Ulcer, 2020 Revised Edition]. Korean J Gastroenterol 2020;76:108-33. [PMID: 32969360 DOI: 10.4166/kjg.2020.76.3.108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
34 Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 84] [Article Influence: 20.4] [Reference Citation Analysis]
35 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
36 William JH, Richards K, Danziger J. Magnesium and Drugs Commonly Used in Chronic Kidney Disease. Adv Chronic Kidney Dis 2018;25:267-73. [PMID: 29793666 DOI: 10.1053/j.ackd.2018.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
37 Kurlander JE, Kolbe M, Rubenstein JH, Richardson CR, Heisler M, Weissman A, De Vries R, Saini SD. Internists' Perceptions of Proton Pump Inhibitor Adverse Effects and Impact on Prescribing Practices: Results of a Nationwide Survey. Gastroenterology Res 2018;11:11-7. [PMID: 29511400 DOI: 10.14740/gr944w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Kung Y, Hsu W, Wu M, Wang J, Liu C, Su Y, Kuo C, Kuo F, Wu D, Wang Y. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci 2017;62:3298-316. [DOI: 10.1007/s10620-017-4830-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
39 Hwang IC, Chang J, Park SM. Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study. PLoS One 2018;13:e0203918. [PMID: 30208110 DOI: 10.1371/journal.pone.0203918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Lai S. Proton Pump Inhibitors and Fracture Risk. Am J Gastroenterol 2019;114:1693-1693. [DOI: 10.14309/ajg.0000000000000342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Tang C, Chen Z, Dai X, Zhu W, Zhong D, Chen X. Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors. Drug Metab Dispos 2019;47:657-64. [PMID: 30962289 DOI: 10.1124/dmd.118.086090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ, Yang YX, Laine L, Weissman A, Saini SD. Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey. Am J Gastroenterol 2020;115:689-96. [PMID: 32091419 DOI: 10.14309/ajg.0000000000000558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
43 Katz PO, Katzka DA. Getting into a TIF(F) Over Fundoplication. Gastroenterology 2018;154:1227-8. [PMID: 29510128 DOI: 10.1053/j.gastro.2018.03.005] [Reference Citation Analysis]
44 Han J, Chin M, Fortinsky KJ, Sharaiha R, Gostout CJ, Chang KJ. Endoscopic augmentation of gastroesophageal junction using a full-thickness endoscopic suturing device. Endosc Int Open. 2018;6:E1120-E1125. [PMID: 30211301 DOI: 10.1055/a-0603-3693] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
45 Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, Francese M, Imazio M, Riccio E, Rossini R, Scotto di Uccio F, Soncini M, Zullo A, Colivicchi F, Di Lenarda A, Gulizia MM, Monica F. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021;85:1-13. [PMID: 33279389 DOI: 10.1016/j.ejim.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Singh-Franco D, Mastropietro DR, Metzner M, Dressler MD, Fares A, Johnson M, De La Rosa D, Wolowich WR. Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid suppressive therapy upon discharge: A systematic review and meta-analysis. PLoS One 2020;15:e0243134. [PMID: 33270710 DOI: 10.1371/journal.pone.0243134] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Yoon YH, Park KW, Lee SH, Park HS, Chang JW, Koo BS. Efficacy of three proton‐pump inhibitor therapeutic strategies on laryngopharyngeal reflux disease; a prospective randomized double‐blind study. Clin Otolaryngol 2019;44:612-8. [DOI: 10.1111/coa.13345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Kurlander JE, Kennedy JK, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Saini SD. Patients' Perceptions of Proton Pump Inhibitor Risks and Attempts at Discontinuation: A National Survey. Am J Gastroenterol 2019;114:244-9. [DOI: 10.14309/ajg.0000000000000061] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
49 Mahawar KK. Incidence of Marginal Ulcers After Gastric Bypass Seems to Be Inversely Related to the Duration of Prophylaxis with Proton Pump Inhibitors. Obes Surg 2021;31:1357-8. [PMID: 33068262 DOI: 10.1007/s11695-020-05050-w] [Reference Citation Analysis]
50 Yasuda JL, Clark SJ, Staffa SJ, Blansky B, Ngo PD, Hamilton TE, Smithers CJ, Jennings R, Manfredi MA. Esophagitis in Pediatric Esophageal Atresia: Acid May Not Always Be the Issue. Journal of Pediatric Gastroenterology & Nutrition 2019;69:163-70. [DOI: 10.1097/mpg.0000000000002336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Yuan J, Zhang C, Sparks JA, Malspeis S, Tsoi KK, Kim JH, Fisher BA, Gao F, Sumerlin T, Liu Y, Liu Y, Pan Y, He Y, Sung JJY. Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study. Aliment Pharmacol Ther 2020;52:449-58. [PMID: 32598046 DOI: 10.1111/apt.15834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Hayward S, Hole B, Denholm R, Duncan P, Morris JE, Fraser SDS, Payne RA, Roderick P, Chesnaye NC, Wanner C, Drechsler C, Postorino M, Porto G, Szymczak M, Evans M, Dekker FW, Jager KJ, Caskey FJ; EQUAL Study investigators. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study. Nephrol Dial Transplant 2021;36:503-11. [PMID: 32543669 DOI: 10.1093/ndt/gfaa064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Enslin S, Kaul V. Barrett's Esophagus Management in the Elderly: Principles and Best Practice. Curr Gastroenterol Rep 2020;22:37. [PMID: 32542508 DOI: 10.1007/s11894-020-00774-2] [Reference Citation Analysis]
54 Xin C, Dong Z, Lin M, Li GH. The impact of pharmaceutical interventions on the rational use of proton pump inhibitors in a Chinese hospital. Patient Prefer Adherence 2018;12:21-6. [PMID: 29343945 DOI: 10.2147/PPA.S150388] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Färkkilä M, Lynge E, Pukkala E, Romundstad P, Tryggvadóttir L, -Chelpin MVE, Lagergren J. Survival after antireflux surgery versus medication in patients with reflux oesophagitis or Barrett's oesophagus: multinational cohort study. Br J Surg 2021;108:864-70. [PMID: 33724340 DOI: 10.1093/bjs/znab024] [Reference Citation Analysis]
56 Wang KN, Bell JS, Tan ECK, Gilmartin-Thomas JFM, Dooley MJ, Ilomäki J. Proton Pump Inhibitors and Infection-Related Hospitalizations Among Residents of Long-Term Care Facilities: A Case-Control Study. Drugs Aging 2019;36:1027-34. [PMID: 31485926 DOI: 10.1007/s40266-019-00704-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Henderson AF, Khan SM, Hornung LN, Mukkada VA, Kalkwarf HJ. Prevalence and Predictors of Compromised Bone Mineral Density in Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 2020;71:764-70. [PMID: 32740533 DOI: 10.1097/MPG.0000000000002866] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol 2019;26:114-20. [PMID: 30976616 DOI: 10.1159/000488506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Medina AL, Troendle DM, Park JY, Thaker A, Dunbar KB, Cheng E. Eosinophilic esophagitis, Barrett's esophagus and esophageal neoplasms in the pediatric patient: a narrative review. Transl Gastroenterol Hepatol 2021;6:32. [PMID: 34423153 DOI: 10.21037/tgh-20-223] [Reference Citation Analysis]
61 Watanabe K, Shimodaira Y, Takahashi S, Fukuda S, Koizumi S, Matsuhashi T, Iijima K. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection. Am J Gastroenterol 2021;116:1632-7. [PMID: 33989224 DOI: 10.14309/ajg.0000000000001309] [Reference Citation Analysis]
62 Stern EK, Carlson DA, Falmagne S, Hoffmann AD, Carns M, Pandolfino JE, Hinchcliff M, Brenner DM. Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil. 2018;30. [PMID: 29110377 DOI: 10.1111/nmo.13247] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
63 Fan WJ, Hou YT, Sun XH, Li XQ, Wang ZF, Guo M, Zhu LM, Wang N, Yu K, Li JN, Ke MY, Fang XC. Effect of high-fat, standard, and functional food meals on esophageal and gastric pH in patients with gastroesophageal reflux disease and healthy subjects. J Dig Dis 2018;19:664-73. [PMID: 30270576 DOI: 10.1111/1751-2980.12676] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
64 Gyawali CP. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe. Curr Gastroenterol Rep 2017;19. [DOI: 10.1007/s11894-017-0586-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
65 Moayyedi P. How to advise patients on the risk of chronic proton pump inhibitor therapy. Curr Opin Gastroenterol 2020;36:317-22. [PMID: 32487851 DOI: 10.1097/MOG.0000000000000641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
66 Mishuk AU, Chen L, Gaillard P, Westrick S, Hansen RA, Qian J. National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002-2017. J Am Pharm Assoc (2003) 2020:S1544-3191(20)30476-3. [PMID: 34756356 DOI: 10.1016/j.japh.2020.09.015] [Reference Citation Analysis]
67 Kahrilas P, Yadlapati R, Roman S. Emerging dilemmas in the diagnosis and management of gastroesophageal reflux disease. F1000Res 2017;6:1748. [PMID: 29034088 DOI: 10.12688/f1000research.11918.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
68 da Silva DT, Rodrigues RF, Machado NM, Maurer LH, Ferreira LF, Somacal S, da Veiga ML, Rocha MIUMD, Vizzotto M, Rodrigues E, Barcia MT, Emanuelli T. Natural deep eutectic solvent (NADES)-based blueberry extracts protect against ethanol-induced gastric ulcer in rats. Food Res Int 2020;138:109718. [PMID: 33292963 DOI: 10.1016/j.foodres.2020.109718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
69 Ma C, Shaheen AA, Congly SE, Andrews CN, Moayyedi P, Forbes N. Interpreting Reported Risks Associated With Use of Proton Pump Inhibitors: Residual Confounding in a 10-Year Analysis of National Ambulatory Data. Gastroenterology 2020;158:780-782.e3. [DOI: 10.1053/j.gastro.2019.10.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
70 Xia B, Yang M, Nguyen LH, He Q, Zhen J, Yu Y, Di M, Qin X, Lu K, Kuo ZC, He Y, Zhang C, Meng W, Yuan J. Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts. Gastroenterology 2021:S0016-5085(21)03350-3. [PMID: 34389338 DOI: 10.1053/j.gastro.2021.08.005] [Reference Citation Analysis]
71 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153:35-48. [PMID: 28528705 DOI: 10.1053/j.gastro.2017.04.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 146] [Article Influence: 39.6] [Reference Citation Analysis]
72 Di Martino E, Provenzani A, Polidori P. Evidence-based application of explicit criteria to assess the appropriateness of geriatric prescriptions at admission and hospital stay. PLoS One 2020;15:e0238064. [PMID: 32841285 DOI: 10.1371/journal.pone.0238064] [Reference Citation Analysis]
73 Tyberg A, Choi A, Gaidhane M, Kahaleh M. Transoral incisional fundoplication for reflux after peroral endoscopic myotomy: a crucial addition to our arsenal. Endosc Int Open. 2018;6:E549-E552. [PMID: 29756011 DOI: 10.1055/a-0584-6802] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
74 Rabach L, Saad AR, Velanovich V. How to choose among fundoplication, magnetic sphincter augmentation or transoral incisionless fundoplication. Curr Opin Gastroenterol 2019;35:371-8. [PMID: 31033771 DOI: 10.1097/MOG.0000000000000550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
75 Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33:614-624. [PMID: 30071147 DOI: 10.1002/ncp.10181] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
76 He Q, Xia B, Meng W, Fan D, Kuo ZC, Huang J, Qin X, Zou H, He Y, Zhang C, Fang S, Pan Y, Yang M, Yuan J. No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants. Am J Gastroenterol 2021. [PMID: 34313608 DOI: 10.14309/ajg.0000000000001377] [Reference Citation Analysis]
77 Kim J, Blackett JW, Jodorkovsky D. Strategies for Effective Discontinuation of Proton Pump Inhibitors. Curr Gastroenterol Rep 2018;20:27. [PMID: 29767318 DOI: 10.1007/s11894-018-0632-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
78 Steinbach EC, Hernandez M, Dellon ES. Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 2018;6:1483-95. [PMID: 30201096 DOI: 10.1016/j.jaip.2018.06.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
79 Hong Y, Ye Z, Gao Z, Rao Y. Continuous improvement on the rationality of prophylactic injectable PPIs usage by a clinical pharmacist-led guidance team at a Chinese tertiary teaching hospital. J Int Med Res 2020;48:300060520954729. [PMID: 33045898 DOI: 10.1177/0300060520954729] [Reference Citation Analysis]
80 Landi SN, Sandler RS, Pate V, Lund JL. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002–2014). Gastroenterology 2018;154:861-873.e6. [DOI: 10.1053/j.gastro.2017.10.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
81 Barletta JF, Buckley MS, MacLaren R. The SUP-ICU Trial: Does It Confirm or Condemn the Practice of Stress Ulcer Prophylaxis? Hosp Pharm 2020;55:96-101. [PMID: 32214442 DOI: 10.1177/0018578719867687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Zhong H, Lin D, Lu Z, Yang W, Chen Y. Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: A meta-analysis. J Clin Pharm Ther 2019;44:209-15. [DOI: 10.1111/jcpt.12769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
83 Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Franceschelli S, Gatta DMP, Pesce M, Ferrone A, Di Martino G, Di Nicola M, De Lutiis MA, Vitacolonna E, Patruno A, Grilli A, Felaco M, Speranza L. Modulation of the oxidative plasmatic state in gastroesophageal reflux disease with the addition of rich water molecular hydrogen: A new biological vision. J Cell Mol Med 2018;22:2750-9. [PMID: 29512923 DOI: 10.1111/jcmm.13569] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
85 Vatcharavongvan P, Puttawanchai V. Potentially inappropriate medications among the elderly in primary care in Thailand from three different sets of criteria. Pharm Pract (Granada) 2019;17:1494. [PMID: 31592037 DOI: 10.18549/PharmPract.2019.3.1494] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
86 Krigel A, Lebwohl B, Yadlapati R, Jodorkovsky D. Association of patient gender and gastroenterologists' diagnosis and management choices in gastroesophageal reflux disease. Dis Esophagus 2021;34:doab019. [PMID: 33870435 DOI: 10.1093/dote/doab019] [Reference Citation Analysis]
87 Yang YSH, Chang HW, Lin IH, Chien LN, Wu MJ, Liu YR, Chu PG, Xie G, Dong F, Jia W, Chang VHS, Yen Y. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Sci Rep 2020;10:866. [PMID: 31964941 DOI: 10.1038/s41598-020-57612-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
88 Zheng Z, Liu X, Xin C, Zhang W, Gao Y, Zeng N, Li M, Cai J, Meng F, Liu D, Zhang J, Yin J, Zhang J, Zhang Z. A new technique for treating hiatal hernia with gastroesophageal reflux disease: the laparoscopic total left-side surgical approach. BMC Surg 2021;21:361. [PMID: 34627222 DOI: 10.1186/s12893-021-01356-3] [Reference Citation Analysis]
89 Castro-Rodríguez A, Machado-Duque ME, Gaviria-Mendoza A, Medina-Morales DA, Álvarez-Vera T, Machado-Alba JE. Factors related to excessive polypharmacy (≥15 medications) in an outpatient population from Colombia. Int J Clin Pract 2018;:e13278. [PMID: 30269404 DOI: 10.1111/ijcp.13278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
90 Tan MC, El-serag HB, Yu X, Thrift AP. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther 2018;48:469-77. [DOI: 10.1111/apt.14895] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
91 Rane MA, Gitin A, Fiedler B, Fiedler L, Hennekens CH. Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs. J Cardiovasc Pharmacol Ther 2020;25:3-6. [DOI: 10.1177/1074248419871902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
92 Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol 2018;9:1142. [PMID: 30671013 DOI: 10.3389/fneur.2018.01142] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
93 Kosedo I, Tokushige A, Takumi T, Yoshikawa A, Teraguchi K, Takenouchi K, Shiraishi K, Ikeda D, Imamura M, Sonoda T, Kanda D, Ikeda Y, Ido A, Ohishi M. Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry. Eur J Intern Med 2020;72:79-87. [PMID: 31735546 DOI: 10.1016/j.ejim.2019.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
94 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
95 Kempenich JW, Sirinek KR. Acid Peptic Disease. Surg Clin North Am 2018;98:933-44. [PMID: 30243454 DOI: 10.1016/j.suc.2018.06.003] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
96 Yu L, Li R, Liu W, Zhou Y, Li Y, Qin Y, Chen Y, Xu Y. Protective Effects of Wheat Peptides against Ethanol-Induced Gastric Mucosal Lesions in Rats: Vasodilation and Anti-Inflammation. Nutrients 2020;12:E2355. [PMID: 32784583 DOI: 10.3390/nu12082355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
97 Goh KL, Lee YY, Leelakusolvong S, Makmun D, Maneerattanaporn M, Quach DT, Raja Ali RA, Sollano JD, Tran VH, Wong RK. Consensus statements and recommendations on the management of mild-to-moderate gastroesophageal reflux disease in the Southeast Asian region. JGH Open 2021;5:855-63. [PMID: 34386592 DOI: 10.1002/jgh3.12602] [Reference Citation Analysis]
98 Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018;93:240-246. [PMID: 29406201 DOI: 10.1016/j.mayocp.2017.10.022] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 26.3] [Reference Citation Analysis]
99 Thong BKS, Ima-Nirwana S, Chin KY. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. Int J Environ Res Public Health 2019;16:E1571. [PMID: 31060319 DOI: 10.3390/ijerph16091571] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
100 Shakhmatova OO, Komarov AL, Korobkova VV, Yarovaya EB, Andreevskaya MV, Shuleshova AG, Panchenko EP. [Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy "REGATТA" results)]. Ter Arkh 2020;92:30-8. [PMID: 33346428 DOI: 10.26442/00403660.2020.09.000699] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Walker J, Hutchison P, Ge J, Zhao D, Wang Y, Rothwell PM, Gaziano JM, Chan A, Burn J, Chia J, Langley R, O'Donnell V, Rocca B, Hawkey C. Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin. Ecancermedicalscience 2018;12:813. [PMID: 29515654 DOI: 10.3332/ecancer.2018.813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, Lee JH, Yang HJ, Cho YK, Bang CS, Kim BJ, Jung HK, Kim BW, Lee YC; Korean College of Helicobacter Upper Gastrointestinal Research. Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition.Gut Liver. 2020;14:707-726. [PMID: 33191311 DOI: 10.5009/gnl20246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Joo MK, Park JJ, Chun HJ. Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol 2019; 25(17): 2058-2070 [PMID: 31114133 DOI: 10.3748/wjg.v25.i17.2058] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
104 Holm A, Lawesson SS, Zolfagharian S, Swahn E, Ekstedt M, Alfredsson J. Bleeding complications after myocardial infarction in a real world population - An observational retrospective study with a sex perspective. Thromb Res 2018;167:156-63. [PMID: 29857272 DOI: 10.1016/j.thromres.2018.05.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
105 Wei J, Chan AT, Zeng C, Bai X, Lu N, Lei G, Zhang Y. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study. Bone 2020;139:115502. [PMID: 32593677 DOI: 10.1016/j.bone.2020.115502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
106 Robinson LB, Camargo CA Jr. Acid suppressant medications and the risk of allergic diseases. Expert Rev Clin Immunol 2018;14:771-80. [PMID: 30113236 DOI: 10.1080/1744666X.2018.1512405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
107 Konstantinidou SK, Kostaras P, Anagnostopoulos GE, Markantonis SL, Karalis V, Konstantinidis K. A retrospective study on the evaluation of the symptoms, medications and improvement of the quality of life of patients undergoing robotic surgery for gastroesophageal reflux disease. Exp Ther Med 2021;21:174. [PMID: 33456541 DOI: 10.3892/etm.2020.9605] [Reference Citation Analysis]
108 Kim JH, Lee YC, Kim EH, Park JC, Shin SK, Lee SK, Jung DH, Park JJ, Youn YH, Park H. The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study. Gut Liver 2019;13:642-8. [PMID: 30970442 DOI: 10.5009/gnl18378] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
109 Sebastián Domingo JJ. Omeprazole-induced hallucinations. Not as rare as you might think. Gastroenterol Hepatol 2018;41:266-7. [PMID: 28625416 DOI: 10.1016/j.gastrohep.2017.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
110 García-Rayado G, Sostres C, Lanas A. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. Expert Rev Clin Pharmacol 2017;10:875-88. [PMID: 28463532 DOI: 10.1080/17512433.2017.1324782] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
111 Shi X, Li X, Ma J, Che H, Ma X, Xie J, Yin X, Wu H, Lv L, Chen T, Zhang J, Zeng E, Tang X, Wang F. Chinese medicine JQ granule combined with half-dose omeprazole for nonerosive reflux disease: A multicenter, randomized, double-blind, placebo-controlled trial study protocol. European Journal of Integrative Medicine 2019;31:100974. [DOI: 10.1016/j.eujim.2019.100974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Kim J, Nimeri A, Khorgami Z, El Chaar M, Lima AG, Vosburg RW. Metabolic bone changes after bariatric surgery: 2020 update, American Society for Metabolic and Bariatric Surgery Clinical Issues Committee position statement. Surgery for Obesity and Related Diseases 2021;17:1-8. [DOI: 10.1016/j.soard.2020.09.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Famularo G. A Relationship Between Proton Pump Inhibitors and Hypomagnesemia? Mayo Clinic Proceedings 2018;93:1530. [DOI: 10.1016/j.mayocp.2018.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol 2019;123:166-72. [PMID: 31009702 DOI: 10.1016/j.anai.2019.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
115 Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, Cardenas-Villacres D, Carrasco S, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. Molecular pathways driving omeprazole nephrotoxicity. Redox Biol 2020;32:101464. [PMID: 32092686 DOI: 10.1016/j.redox.2020.101464] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
116 de Araújo LML, de Moura Lopes MV, de Arruda RS, Martins RR, Oliveira AG. Proton pump inhibitor and community pharmacies: Usage profile and factors associated with long-term use. PLoS One 2021;16:e0252785. [PMID: 34111166 DOI: 10.1371/journal.pone.0252785] [Reference Citation Analysis]
117 Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
118 Casula M, Scotti L, Galimberti F, Mozzanica F, Tragni E, Corrao G, Catapano AL. Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis 2018;277:123-9. [PMID: 30212680 DOI: 10.1016/j.atherosclerosis.2018.08.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
119 Kroupa R, Katinova I, Pavlik T, Kunovsky L, Prochazka V, Borilova Linhartova P, Packova B, Kala Z, Dolina J. Incidence trends of esophageal cancer in the Czech Republic by histological subtype and stage and prescription rate of acid suppressing drugs. Cancer Epidemiol 2020;69:101853. [PMID: 33161372 DOI: 10.1016/j.canep.2020.101853] [Reference Citation Analysis]
120 Nallapeta N, Reynolds JL, Bakhai S. Deprescribing Proton Pump Inhibitors in an Academic, Primary Care Clinic: Quality Improvement Project. J Clin Gastroenterol 2020;54:864-70. [PMID: 32091449 DOI: 10.1097/MCG.0000000000001317] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
122 Lai SW. Proton pump inhibitors and the risk of pancreatic cancer. J Gastroenterol 2021;56:293-4. [PMID: 33544263 DOI: 10.1007/s00535-021-01764-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
123 Nolde M, Bahls M, Friedrich N, Dörr M, Dreischulte T, Felix SB, Rückert-Eheberg IM, Ahn N, Amann U, Schwedhelm E, Völzke H, Lerch MM, Linseisen J, Meisinger C, Baumeister SE. Association of proton pump inhibitor use with endothelial function and metabolites of the nitric oxide pathway: A cross-sectional study. Pharmacotherapy 2021;41:198-204. [PMID: 33465818 DOI: 10.1002/phar.2504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
124 Calvo LLJ, García Cámara P, Llorente Barrio M, Sierra Gabarda O, Monzón Baez R, Arbonés Mainar JM, Alcedo González J, Bernal Monterde V. Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project. Eur J Clin Pharmacol 2021. [PMID: 34269841 DOI: 10.1007/s00228-021-03186-x] [Reference Citation Analysis]
125 Yu Z, Hu J, Hu Y. Neutropenia and Thrombocytopenia Induced by Proton Pump Inhibitors: A Case Report. Drug Saf Case Rep 2018;5:28. [PMID: 30470925 DOI: 10.1007/s40800-018-0093-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
126 Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Reference Citation Analysis]
127 Tekin S, Dundar S, Demirci F, Bozoglan A, Yildirim TT, Gunes N, Acikan I, Ozcan EC. Biomechanical and biochemical evaluation of the effect of systemic application of omeprazole on the osseointegration of titanium implants. Int J Implant Dent 2021;7:27. [PMID: 33843027 DOI: 10.1186/s40729-021-00310-5] [Reference Citation Analysis]
128 Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. JAMA 2020;324:2536-47. [PMID: 33351048 DOI: 10.1001/jama.2020.21360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
129 Allin KH, Moayyedi P. Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander? Gastroenterology 2021:S0016-5085(21)03478-8. [PMID: 34499912 DOI: 10.1053/j.gastro.2021.09.005] [Reference Citation Analysis]
130 Reumkens A, Bakker CM, van Kraaij SJW, Winkens B, Raijmakers MT, van Nunen AB, van Deursen CTBM, Masclee AAM. Safety of low-volume PEG-asc bowel cleansing preparation for colonoscopy: identifying patients at risk for hypokalemia in a prospective cohort study. Endosc Int Open 2021;9:E1198-204. [PMID: 34447864 DOI: 10.1055/a-1478-3361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Xavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol 2018;25:243-52. [PMID: 30320163 DOI: 10.1159/000487154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
132 Bajaj J, Brenner D, Cai Q, Cash B, Crowell M, Dibaise J, Gallegos-orozco J, Gardner T, Gyawali C, Ha C, Holtmann G, Jamil L, Kaplan G, Karsan H, Kinoshita Y, Lebwohl B, Leontiadis G, Lichtenstein G, Longstreth G, Muthusamy V, Oxentenko A, Pimentel M, Pisegna J, Rubenstein J, Russo M, Saini S, Samadder N, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy B. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. Am J Gastroenterol 2020;115:1007-18. [DOI: 10.14309/ajg.0000000000000709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Gyawali CP, Azagury DE, Chan WW, Chandramohan SM, Clarke JO, Bortoli N, Figueredo E, Fox M, Jodorkovsky D, Lazarescu A, Malfertheiner P, Martinek J, Murayama KM, Penagini R, Savarino E, Shetler KP, Stein E, Tatum RP, Wu J. Nonerosive reflux disease: clinical concepts. Ann N Y Acad Sci 2018;1434:290-303. [DOI: 10.1111/nyas.13845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
134 Miyazaki Y, Ichimura A, Sato S, Fujii T, Oishi S, Sakai H, Takeshima H. The natural flavonoid myricetin inhibits gastric H + , K + -ATPase. European Journal of Pharmacology 2018;820:217-21. [DOI: 10.1016/j.ejphar.2017.12.042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
135 Rosenberg V, Tzadok R, Chodick G, Kariv R. Proton pump inhibitors long term use-trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiol Drug Saf 2021;30:1576-87. [PMID: 34453456 DOI: 10.1002/pds.5352] [Reference Citation Analysis]
136 Buda V, Prelipcean A, Cristescu C, Roja A, Dalleur O, Andor M, Danciu C, Ledeti A, Dehelean CA, Cretu O. Prescription Habits Related to Chronic Pathologies of Elderly People in Primary Care in the Western Part of Romania: Current Practices, International Recommendations, and Future Perspectives Regarding the Overuse and Misuse of Medicines. Int J Environ Res Public Health 2021;18:7043. [PMID: 34280980 DOI: 10.3390/ijerph18137043] [Reference Citation Analysis]
137 Kurin M, Fass R. Management of Gastroesophageal Reflux Disease in the Elderly Patient. Drugs Aging 2019;36:1073-81. [DOI: 10.1007/s40266-019-00708-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Cerfon MA, Vernaudon J, Gervais F, Morelon E, Coste MH, Krolak-Salmon P, Mouchoux C, Novais T. Drug-related problems in older patients with advanced chronic kidney disease identified during pretransplant comprehensive geriatric assessment. Nephrol Ther 2021:S1769-7255(21)00532-0. [PMID: 34756826 DOI: 10.1016/j.nephro.2021.08.006] [Reference Citation Analysis]
139 Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2020;8:CD013113. [PMID: 32844430 DOI: 10.1002/14651858.CD013113.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
140 Tuppin P, Rivière S, Deutsch D, Gastaldi-Menager C, Sabaté JM. Burden of drug use for gastrointestinal symptoms and functional gastrointestinal disorders in France: a national study using reimbursement data for 57 million inhabitants. Therap Adv Gastroenterol 2019;12:1756284819853790. [PMID: 31320929 DOI: 10.1177/1756284819853790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, Lee YY, Nair AB, Antony PT, Ford AC, Chaiyakunapruk N. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol 2021. [PMID: 34622475 DOI: 10.1111/bcp.15103] [Reference Citation Analysis]
142 Thompson W, Farrell B, Welch V, Tugwell P, Way C, Richardson L, Bjerre LM. Continuation or deprescribing of proton pump inhibitors: A consult patient decision aid. Can Pharm J (Ott) 2019;152:18-22. [PMID: 30719193 DOI: 10.1177/1715163518816719] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
143 Shim YK, Kim N. The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. Korean J Gastroenterol 2017;70:4-12. [PMID: 28728310 DOI: 10.4166/kjg.2017.70.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
144 Demcsák A, Soós A, Kincses L, Capunge I, Minkov G, Kovacheva-Slavova M, Nakov R, Wu D, Huang W, Xia Q, Deng L, Hollenbach M, Schneider A, Hirth M, Ioannidis O, Vincze Á, Bajor J, Sarlós P, Czakó L, Illés D, Izbéki F, Gajdán L, Papp M, Hamvas J, Varga M, Kanizsai P, Bóna E, Mikó A, Váncsa S, Juhász MF, Ocskay K, Darvasi E, Miklós E, Erőss B, Szentesi A, Párniczky A, Casadei R, Ricci C, Ingaldi C, Mastrangelo L, Jovine E, Cennamo V, Marino MV, Barauskas G, Ignatavicius P, Pelaez-Luna M, Rios AS, Turcan S, Tcaciuc E, Małecka-Panas E, Zatorski H, Nunes V, Gomes A, Gonçalves TC, Freitas M, Constantino J, Sá M, Pereira J, Mateescu B, Constantinescu G, Sandru V, Negoi I, Ciubotaru C, Negoita V, Bunduc S, Gheorghe C, Barbu S, Tantau A, Tantau M, Dumitru E, Suceveanu AI, Tocia C, Gherbon A, Litvin A, Shirinskaya N, Rabotyagova Y, Bezmarevic M, Hegyi PJ, Han J, Rodriguez-Oballe JA, Salas IM, Comas EP, Garcia DI, Cuadrado AJ, Castiñeira AQ, Chang YT, Chang MC, Kchaou A, Tlili A, Kacar S, Gökbulut V, Duman D, Kani HT, Altintas E, Chooklin S, Chuklin S, Gougol A, Papachristou G, Hegyi P. Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis - An international cohort study. Pancreatology 2020;20:1323-31. [PMID: 32948430 DOI: 10.1016/j.pan.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Miller JW. Proton Pump Inhibitors, H2-Receptor Antagonists, Metformin, and Vitamin B-12 Deficiency: Clinical Implications. Adv Nutr 2018;9:511S-8S. [PMID: 30032223 DOI: 10.1093/advances/nmy023] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
146 Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, Wettermark B, Ärnlöv J, Janmaat CJ, Lindholm B, Dekker FW, Coresh J, Grams ME, Carrero JJ. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology 2017;153:702-10. [PMID: 28583827 DOI: 10.1053/j.gastro.2017.05.046] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
147 Iglesia EGA, Reed CC, Nicolai EA, Dellon ES. Dietary Elimination Therapy Is Effective in Most Adults With Eosinophilic Esophagitis Responsive to Proton Pump Inhibitors. Clin Gastroenterol Hepatol 2020;18:1638-1640.e2. [PMID: 31408702 DOI: 10.1016/j.cgh.2019.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
148 Fattahi MR, Niknam R, Shams M, Anushiravani A, Taghavi SA, Omrani GR, Mahmoudi L. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density. Risk Manag Healthc Policy 2019;12:349-55. [PMID: 31853206 DOI: 10.2147/RMHP.S223118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
149 Gong Y, Huang X, Chen M, Xiong L. Teprenone improves gastric mucosal injury and dyspeptic symptoms in long-term nonsteroidal anti-inflammatory drug users. J Gastroenterol Hepatol 2019;34:1344-50. [PMID: 30681185 DOI: 10.1111/jgh.14614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
150 Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA 2021;326:1310-8. [PMID: 34609446 DOI: 10.1001/jama.2021.14920] [Reference Citation Analysis]
151 Kavitt RT, Lipowska AM, Anyane-yeboa A, Gralnek IM. Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine 2019;132:447-56. [DOI: 10.1016/j.amjmed.2018.12.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
152 Duncan DR, Mitchell PD, Larson K, McSweeney ME, Rosen RL. Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia. JAMA Otolaryngol Head Neck Surg 2018;144:1116-24. [PMID: 30325987 DOI: 10.1001/jamaoto.2018.1919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
153 Scarpignato C, Tolone S. Addressing long-term PPI safety. Digestive and Liver Disease 2020;52:853-6. [DOI: 10.1016/j.dld.2020.05.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol 2019;33:327-38. [PMID: 30625254 DOI: 10.1111/fcp.12436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
155 Park Y, Hwang DW, Lee JH, Song KB, Jun E, Lee W, Kwon J, Kim SC. Analysis of Symptomatic Marginal Ulcers in Patients Who Underwent Pancreaticoduodenectomy for Periampullary Tumors. Pancreas 2020;49:208-15. [PMID: 32011522 DOI: 10.1097/MPA.0000000000001470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 Mehta N, Martinez Guasch F, Kamen C, Shah S, Burry LD, Soong C, Mehta S. Proton Pump Inhibitors in the Elderly Hospitalized Patient: Evaluating Appropriate Use and Deprescribing. J Pharm Technol 2020;36:54-60. [PMID: 34752519 DOI: 10.1177/8755122519894953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Nehra AK, Alexander JA, Loftus CG, Nehra V. In Reply-A Relationship Between Proton Pump Inhibitors and Hypomagnesemia? Mayo Clin Proc 2018;93:1530-1. [PMID: 30286836 DOI: 10.1016/j.mayocp.2018.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Gagner M. Comment on: Metabolic bone changes after bariatric surgery: 2020 update, American Society for Metabolic and Bariatric Surgery Clinical Issues Committee position statement. Surg Obes Relat Dis 2021;17:1229-30. [PMID: 33622602 DOI: 10.1016/j.soard.2021.01.016] [Reference Citation Analysis]
159 Peterson RM, Kempenich JW. Management of Marginal Ulcers. In: Nguyen NT, Brethauer SA, Morton JM, Ponce J, Rosenthal RJ, editors. The ASMBS Textbook of Bariatric Surgery. Cham: Springer International Publishing; 2020. pp. 225-34. [DOI: 10.1007/978-3-030-27021-6_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Wiens E, Kovaltchouk U, Koomson A, Targownik LE. The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. J Clin Gastroenterol 2019;53:553-9. [PMID: 31356559 DOI: 10.1097/MCG.0000000000001243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Rababa M, Rababa'h A. Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors. BMC Geriatr 2020;20:431. [PMID: 33121444 DOI: 10.1186/s12877-020-01844-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Ong AM, Chua LT, Khor CJ, Asokkumar R, s/o Namasivayam V, Wang Y. Diaphragmatic Breathing Reduces Belching and Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms. Clinical Gastroenterology and Hepatology 2018;16:407-416.e2. [DOI: 10.1016/j.cgh.2017.10.038] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
163 Avraham O, Biglow M. Implementation of Proton Pump Inhibitor Deprescription Protocol in Geriatric Residents. Ann Pharmacother 2018;52:747-53. [PMID: 29473423 DOI: 10.1177/1060028018759747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
164 Lin YT, Lin TY, Hung SC, Liu PY, Wu PH, Chuang YS, Hung WC, Chiu YW, Kuo MC, Wu CY. Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients. Microorganisms 2021;9:286. [PMID: 33573326 DOI: 10.3390/microorganisms9020286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
165 Renom-guiteras A, Thürmann PA, Miralles R, Klaaßen-mielke R, Thiem U, Stephan A, Bleijlevens MHC, Jolley D, Leino-kilpi H, Rahm Hallberg I, Saks K, Soto-martin M, Zabalegui A, Meyer G; on behalf of the RightTimePlaceCare Consortium. Potentially inappropriate medication among people with dementia in eight European countries. Age and Ageing 2018;47:68-74. [DOI: 10.1093/ageing/afx147] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
166 Spencer A, Quimby JM, Price JM, MacLane S, Hillsman S, Secoura P, Steiner JM, Katherine Tolbert M. Appetite-stimulating effects of once-daily omeprazole in cats with chronic kidney disease: Double-blind, placebo-controlled, randomized, crossover trial. J Vet Intern Med 2021. [PMID: 34590746 DOI: 10.1111/jvim.16268] [Reference Citation Analysis]
167 Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? Eur J Intern Med 2020;72:15-26. [PMID: 31796246 DOI: 10.1016/j.ejim.2019.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
168 Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol 2018;74:45-52. [PMID: 28986609 DOI: 10.1007/s00228-017-2324-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
169 Mafi JN, May FP, Kahn KL, Chong M, Corona E, Yang L, Mongare MM, Nair V, Reynolds C, Gupta R, Damberg CL, Esrailian E, Sarkisian C. Low-Value Proton Pump Inhibitor Prescriptions Among Older Adults at a Large Academic Health System. J Am Geriatr Soc 2019;67:2600-4. [PMID: 31486549 DOI: 10.1111/jgs.16117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
170 Horvath A, Leber B, Feldbacher N, Steinwender M, Komarova I, Rainer F, Blesl A, Stadlbauer V. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep 2020;10:2723. [PMID: 32066847 DOI: 10.1038/s41598-020-59550-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
171 MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract 2018;7:41-52. [PMID: 29892570 DOI: 10.2147/IPRP.S142932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
172 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
173 Hannan N, Steel A, McMillan SS, Tiralongo E. Health Service Use and Treatment Choices for Pediatric Eosinophilic Esophagitis: Findings From a Cross-Sectional Survey of Australian Carers. Front Pediatr 2020;8:147. [PMID: 32363170 DOI: 10.3389/fped.2020.00147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
174 Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis. Stroke 2018;49:312-8. [PMID: 29339434 DOI: 10.1161/STROKEAHA.117.019166] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
175 Shi D, Zhou Z, Dai Y, Pan X, Cao Q. Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clin Drug Investig 2019;39:847-56. [DOI: 10.1007/s40261-019-00810-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Shinozaki S, Osawa H, Kobayashi Y, Sakamoto H, Hayashi Y, Miura Y, Kawarai Lefor A, Yamamoto H. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan. Scand J Gastroenterol 2018;53:897-904. [PMID: 30056768 DOI: 10.1080/00365521.2018.1486883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
177 MacDonell SO, Miller JC, Harper MJ, Reid MR, Haszard JJ, Gibson RS, Houghton LA. Multiple Micronutrients, Including Zinc, Selenium and Iron, Are Positively Associated with Anemia in New Zealand Aged Care Residents. Nutrients 2021;13:1072. [PMID: 33806205 DOI: 10.3390/nu13041072] [Reference Citation Analysis]
178 Lai S, Lin C, Lin C, Liao K. Proton pump inhibitors therapy and the risk of hip fracture in older people in Taiwan. Eur Geriatr Med 2018;9:169-74. [DOI: 10.1007/s41999-017-0022-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
179 Yan M, Wu ZF, Tang D, Wang F, Xiao YW, Xu P, Zhang BK, Liu YP, Xiang DX, Banh HL. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Biomed Pharmacother 2018;108:60-4. [PMID: 30216801 DOI: 10.1016/j.biopha.2018.08.121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
180 Scarpignato C, Sloan JA, Wang DH, Hunt RH. Gastrointestinal pharmacology: practical tips for the esophagologist. Ann N Y Acad Sci 2020;1481:90-107. [PMID: 32822080 DOI: 10.1111/nyas.14447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Kuo CJ, Lin CY, Chen CW, Hsu CY, Hsieh SY, Chiu CT, Lin WR. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study. J Pers Med 2021;11:1063. [PMID: 34834415 DOI: 10.3390/jpm11111063] [Reference Citation Analysis]
182 Cohen SM, Lee HJ, Leiman DA, Roy N, Misono S. Associations between Community-Acquired Pneumonia and Proton Pump Inhibitors in the Laryngeal/Voice-Disordered Population. Otolaryngol Head Neck Surg 2019;160:519-25. [PMID: 30419774 DOI: 10.1177/0194599818811292] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
183 Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc 2021;22:15-22. [PMID: 33321078 DOI: 10.1016/j.jamda.2020.09.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
184 Lai SW, Kuo YH, Liao KF. Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis 2020;79:e156. [PMID: 31300456 DOI: 10.1136/annrheumdis-2019-215982] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
185 Bilal M, Samuel R, Khalil MK, Singh S, Parupudi S, Abougergi MS. Nonvariceal upper GI hemorrhage after percutaneous coronary intervention for acute myocardial infarction: a national analysis over 11 months. Gastrointestinal Endoscopy 2020;92:65-74.e2. [DOI: 10.1016/j.gie.2020.01.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
186 Rochoy M, Dubois S, Glantenet R, Gautier S, Lambert M. Le rebond d’acidité gastrique après arrêt d’un inhibiteur de la pompe à protons : revue narrative de littérature. Therapies 2018;73:237-46. [DOI: 10.1016/j.therap.2017.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Zhuang QJ, Tan ND, Chen SF, Zhang MY, Xiao YL. Magnetic sphincter augmentation in treating refractory gastroesophageal reflux disease: A systematic review and meta-analysis. J Dig Dis 2021. [PMID: 34693633 DOI: 10.1111/1751-2980.13063] [Reference Citation Analysis]
188 Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K. Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels. JAMA Netw Open 2018;1:e186343. [PMID: 30646328 DOI: 10.1001/jamanetworkopen.2018.6343] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
189 Imfeld P, Bodmer M, Jick SS, Meier CR. Proton Pump Inhibitor Use and Risk of Developing Alzheimer’s Disease or Vascular Dementia: A Case–Control Analysis. Drug Saf 2018;41:1387-96. [DOI: 10.1007/s40264-018-0704-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
190 Lai SW, Lin CL, Liao KF. Proton pump inhibitors therapy and the risk of major osteoporotic nonhip fractures in older adults in Taiwan. Eur J Gastroenterol Hepatol 2019;31:272-3. [PMID: 30575640 DOI: 10.1097/MEG.0000000000001312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
191 Mangan JJ 3rd, Divi SN, McKenzie JC, Stull JD, Conaway W, Casper DS, Goyal DKC, Nicholson KJ, Galetta MS, Wagner SC, Kaye ID, Kurd MF, Woods BI, Radcliff KE, Rihn JA, Anderson DG, Hilibrand AS, Vaccaro AR, Schroeder GD, Kepler CK. Proton Pump Inhibitor Use Affects Pseudarthrosis Rates and Influences Patient-Reported Outcomes. Global Spine J 2020;10:55-62. [PMID: 32002350 DOI: 10.1177/2192568219853222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange AH, Srinivas N, Sange I. Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol. Cureus 2021;13:e16744. [PMID: 34354892 DOI: 10.7759/cureus.16744] [Reference Citation Analysis]
193 Harewood R, Disney R, Kinross J, von Wagner C, Cross AJ. Medication use and risk of proximal colon cancer: a systematic review of prospective studies with narrative synthesis and meta-analysis. Cancer Causes Control 2021;32:1047-61. [PMID: 34224060 DOI: 10.1007/s10552-021-01472-8] [Reference Citation Analysis]
194 Giannini EG, Bodini G, Furnari M, Marabotto E. Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. Clin Gastroenterol Hepatol 2021;19:410. [PMID: 33248110 DOI: 10.1016/j.cgh.2020.04.027] [Reference Citation Analysis]
195 Fischbach W, Hünger B, Hünger M. [Appropriateness of Proton pump inhibitor (PPI) recommendation in discharge letters of a gastroenterological department]. Z Gastroenterol 2021. [PMID: 34687032 DOI: 10.1055/a-1550-3064] [Reference Citation Analysis]
196 Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urol Nephrol 2021;73:462-70. [PMID: 33769018 DOI: 10.23736/S2724-6051.21.04116-3] [Reference Citation Analysis]
197 Rogers BD, Gyawali CP. Why differences between New York and New Delhi matter in approach to gastroesophageal reflux disease. Indian J Gastroenterol 2019;38:371-7. [DOI: 10.1007/s12664-019-00987-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
198 Wang YP, Herndon CC, Lu CL. Non-pharmacological Approach in the Management of Functional Dyspepsia. J Neurogastroenterol Motil 2020;26:6-15. [PMID: 31751504 DOI: 10.5056/jnm19005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Corley DA. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. Gastroenterology 2019;157:604-7. [DOI: 10.1053/j.gastro.2019.07.039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
200 Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci 2020;1481:43-58. [PMID: 32761834 DOI: 10.1111/nyas.14428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
201 Sumi K, Inoue H, Kobayashi Y, Iwaya Y, Abad MRA, Fujiyoshi Y, Shimamura Y, Ikeda H, Onimaru M. Endoscopic treatment of proton pump inhibitor‐refractory gastroesophageal reflux disease with anti‐reflux mucosectomy: Experience of 109 cases. Digestive Endoscopy 2021;33:347-54. [DOI: 10.1111/den.13727] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
202 Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastro 2018;16:570-90. [DOI: 10.1007/s11938-018-0206-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
203 Yuan J, He Q, Nguyen LH, Wong MCS, Huang J, Yu Y, Xia B, Tang Y, He Y, Zhang C. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2021;70:1070-7. [PMID: 32989021 DOI: 10.1136/gutjnl-2020-322557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
204 Derwich M, Mitus-Kenig M, Pawlowska E. Orally Administered NSAIDs-General Characteristics and Usage in the Treatment of Temporomandibular Joint Osteoarthritis-A Narrative Review. Pharmaceuticals (Basel) 2021;14:219. [PMID: 33807930 DOI: 10.3390/ph14030219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
205 Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current Opinion in Gastroenterology 2017;33:430-8. [DOI: 10.1097/mog.0000000000000392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
206 Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344-55. [DOI: 10.1097/mog.0000000000000543] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
207 Cho NJ, Choi CY, Park S, Park SH, Lee EY, Gil HW. Association of proton pump inhibitor use with renal outcomes in patients with coronary artery disease. Kidney Res Clin Pract 2018;37:59-68. [PMID: 29629278 DOI: 10.23876/j.krcp.2018.37.1.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
208 Aiolfi A, Cavalli M, Saino G, Khor D, Sozzi A, Rausa E, Bonitta G, Bona D. Laparoscopic Toupet Fundoplication for the Treatment of Laryngopharyngeal Reflux: Results at Medium-Term follow-Up. World J Surg 2020;44:3821-8. [PMID: 32588243 DOI: 10.1007/s00268-020-05653-5] [Reference Citation Analysis]
209 Altay MA, Sindel A, Özalp Ö, Yıldırımyan N, Kocabalkan B. Proton pump inhibitor intake negatively affects the osseointegration of dental implants: a retrospective study. J Korean Assoc Oral Maxillofac Surg 2019;45:135-40. [PMID: 31334101 DOI: 10.5125/jkaoms.2019.45.3.135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
210 Walker MJ, Crews NR, El-Halabi M, Fayad NF. Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. Gastroenterology Res 2019;12:305-11. [PMID: 31803310 DOI: 10.14740/gr1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Sugiyama T. Letter: proton pump inhibitor use and fracture risk. Aliment Pharmacol Ther 2018;47:449-50. [PMID: 29314134 DOI: 10.1111/apt.14462] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
212 Kamiński M, Łoniewski I, Misera A, Marlicz W. Heartburn-Related Internet Searches and Trends of Interest across Six Western Countries: A Four-Year Retrospective Analysis Using Google Ads Keyword Planner. Int J Environ Res Public Health 2019;16:E4591. [PMID: 31756947 DOI: 10.3390/ijerph16234591] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
213 . Prescribing PPIs. Drug Ther Bull 2017;55:117-20. [PMID: 29021249 DOI: 10.1136/dtb.2017.10.0541] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
214 Wu PI, Sloan JA, Kuribayashi S, Gregersen H. Impedance in the evaluation of the esophagus. Ann N Y Acad Sci 2020;1481:139-53. [PMID: 32557676 DOI: 10.1111/nyas.14408] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Bor S, Kalkan İH, Çelebi A, Dinçer D, Akyüz F, Dettmar P, Özen H. Alginates: From the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol 2019;30:109-36. [PMID: 31624050 DOI: 10.5152/tjg.2019.19677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
216 Friedman AJ, Elseth AJ, Brockmeyer JR. Proton Pump Inhibitors, Associated Complications, and Alternative Therapies: A Shifting Risk Benefit Ratio. Am Surg 2021;:3134821991988. [PMID: 33560890 DOI: 10.1177/0003134821991988] [Reference Citation Analysis]
217 Kang SJ, Jung HK, Tae CH, Kim SY, Lee KJ. On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis. J Neurogastroenterol Motil 2022;28:5-14. [PMID: 34980685 DOI: 10.5056/jnm21095] [Reference Citation Analysis]
218 Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayama T, Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi H, Itoh Y. The influence of long-term use of proton pump inhibitors on the gut microbiota: An age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100-105. [PMID: 29371761 DOI: 10.3164/jcbn.17-78] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]
219 Yang M, He Q, Gao F, Nirantharakumar K, Veenith T, Qin X, Page AT, Wong MCS, Huang J, Kuo ZC, Xia B, Zhang C, He Y, Meng W, Yuan J, Pan Y. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Med 2021;19:316. [PMID: 34856983 DOI: 10.1186/s12916-021-02180-5] [Reference Citation Analysis]
220 Ghosh G, Schnoll-sussman F, Mathews S, Katz PO. Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns? Aliment Pharmacol Ther 2020;51:121-8. [DOI: 10.1111/apt.15522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
221 Tang C, Zhu Y, Yang X, Xu B, Ye C, Yang Y, Zhong J, Zhao Q, Yu L. Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. J Gastroenterol Hepatol 2020;35:1720-30. [PMID: 32154936 DOI: 10.1111/jgh.15030] [Reference Citation Analysis]
222 He HS, Li BY, Chen QT, Song CY, Shi J, Shi B. Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis. Med Sci Monit 2019;25:1169-76. [PMID: 30755541 DOI: 10.12659/MSM.911886] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
223 Trang A, Bushman J, Halalau A. Effect of Long-Term Proton Pump Inhibitor Use on Glycemic Control in Patients with Type Two Diabetes Mellitus. J Diabetes Res 2021;2021:5578265. [PMID: 34368365 DOI: 10.1155/2021/5578265] [Reference Citation Analysis]
224 Bradley ES, Howe E, Wu X, Haran JP. Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment. Gut Pathog 2019;11:29. [PMID: 31210787 DOI: 10.1186/s13099-019-0309-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
225 Ikuta K, Nakagawa S, Momo K, Yonezawa A, Itohara K, Sato Y, Imai S, Nakagawa T, Matsubara K. Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study. BMJ Open 2021;11:e041543. [PMID: 33589451 DOI: 10.1136/bmjopen-2020-041543] [Reference Citation Analysis]
226 Monta A, Redon S, Fabre C, Donnet A. A retrospective observation on 105 patients with chronic cluster headache receiving indomethacin. Neurol Sci 2021;42:4175-82. [PMID: 33547540 DOI: 10.1007/s10072-021-05114-4] [Reference Citation Analysis]
227 Lieberman JA. Minimally symptomatic patients with eosinophilic esophagitis should still be actively treated-CON. Ann Allergy Asthma Immunol 2019;122:574-5. [PMID: 31171239 DOI: 10.1016/j.anai.2018.11.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
228 Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Current Opinion in Gastroenterology 2018;34:451-7. [DOI: 10.1097/mog.0000000000000471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
229 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
230 Platt KD, Saini SD, Kurlander JE. Selecting the Appropriate Patients for Proton Pump Inhibitor Discontinuation: A Teachable Moment. JAMA Intern Med 2019;179:1276. [DOI: 10.1001/jamainternmed.2019.2382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
231 Zhang B, Ling T, Zhaxi P, Cao Y, Qian L, Zhao D, Kang W, Zhang W, Wang L, Xu G, Zou X. Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression. Cancer Letters 2019;452:23-30. [DOI: 10.1016/j.canlet.2019.03.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
232 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 8.5] [Reference Citation Analysis]
233 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
234 Miyano S, Michihata N, Sada KE, Uda K, Matsui H, Fushimi K, Nangaku M, Yasunaga H. Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study. Rheumatology (Oxford) 2021;60:1717-23. [PMID: 33067623 DOI: 10.1093/rheumatology/keaa594] [Reference Citation Analysis]
235 Liang CS, Bai YM, Hsu JW, Huang KL, Ko NY, Tsai CK, Yeh TC, Chu HT, Tsai SJ, Chen TJ, Chen MH. The Risk of Epilepsy after Long-term Proton Pump Inhibitor Therapy. Seizure 2021;87:88-93. [PMID: 33735722 DOI: 10.1016/j.seizure.2021.03.008] [Reference Citation Analysis]
236 AlMutairi H, O'Dwyer M, McCarron M, McCallion P, Henman MC. The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study. Saudi Pharm J 2018;26:1012-21. [PMID: 30416357 DOI: 10.1016/j.jsps.2018.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Tang C, Li L, Ma X, Wang J, Chen B, Dai X, Zhang Y, Chen X. Qualitative and quantitative determination of anaprazole and its major metabolites in human plasma. J Pharm Biomed Anal 2020;183:113146. [PMID: 32086126 DOI: 10.1016/j.jpba.2020.113146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Petrov RV, Fajardo RA, Bakhos CT, Abbas AE. Peroral endoscopic myotomy: techniques and outcomes. Shanghai Chest 2021;5:14. [PMID: 34013165 DOI: 10.21037/shc.2020.02.02] [Reference Citation Analysis]
239 Aggarwal S, Baksi A, Kamtam DNH. Reply to: Incidence of Marginal Ulcers After Gastric Bypass Seems to Be Inversely Related to the Duration of Prophylaxis with Proton Pump Inhibitors. Obes Surg 2021;31:1359-60. [PMID: 33089384 DOI: 10.1007/s11695-020-05051-9] [Reference Citation Analysis]
240 Muñoz-torrero JFS, Zamorano J, Rico-martín S, Rivas MD, Bacaicoa MA, Robles R, Sanchez-bacaicoa C, Monreal M. Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. Atherosclerosis 2020;292:84-9. [DOI: 10.1016/j.atherosclerosis.2019.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
241 Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis. Rheumatol Int. 2018;38:1999-2014. [PMID: 30159775 DOI: 10.1007/s00296-018-4142-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
242 Chrysant SG. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev Cardiovasc Ther 2019;17:345-51. [PMID: 31092056 DOI: 10.1080/14779072.2019.1615446] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
243 Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52:842-852. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
244 Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
245 Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
246 Righini Grunder F, Petit LM, Ezri J, Jantchou P, Aspirot A, Laberge S, Faure C. Should Proton Pump Inhibitors be Systematically Prescribed in Patients With Esophageal Atresia After Surgical Repair? J Pediatr Gastroenterol Nutr 2019;69:45-51. [PMID: 30889131 DOI: 10.1097/MPG.0000000000002328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
247 Fajardo RA, Petrov RV, Bakhos CT, Abbas AE. Endoscopic and Surgical Treatments for Achalasia: Who to Treat and How? Gastroenterol Clin North Am 2020;49:481-98. [PMID: 32718566 DOI: 10.1016/j.gtc.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
248 Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol 2019; 11(9): 663-677 [PMID: 31598192 DOI: 10.4254/wjh.v11.i9.663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
249 Perera MJ, Schneiderman N, Sotres-Alvarez D, Daviglus M, Mirabal SM, Llabre MM. Are Anxious and Depressive Symptoms Associated with Gastrointestinal Symptoms in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)? J Racial Ethn Health Disparities 2021;8:712-22. [PMID: 32737849 DOI: 10.1007/s40615-020-00831-6] [Reference Citation Analysis]
250 Wong GLH, Lau LHS, Ching JYL, Tse YK, Ling RHY, Wong VWS, Chiu PWY, Lau JYW, Chan FKL. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. Gut 2020;69:652-7. [PMID: 31229990 DOI: 10.1136/gutjnl-2019-318715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
251 Singh-Franco D, Hale G, Jacobs RJ. Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. Hosp Pract (1995) 2018;46:22-9. [PMID: 29224408 DOI: 10.1080/21548331.2018.1415621] [Reference Citation Analysis]
252 Vanclooster A, van Deursen C, Jaspers R, Cassiman D, Koek G. Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial. Gastroenterology 2017;153:678-680.e2. [PMID: 28624580 DOI: 10.1053/j.gastro.2017.06.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
253 Gramont B, Bertoletti L, Roy M, Roblin X, Tardy B, Cathébras P. [Use and management of proton pump inhibitors: An observational study]. Therapie 2020;75:649-62. [PMID: 32591130 DOI: 10.1016/j.therap.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
254 Targownik L. Discontinuing Long-Term PPI Therapy: Why, With Whom, and How? American Journal of Gastroenterology 2018;113:519-28. [DOI: 10.1038/ajg.2018.29] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
255 Kanno T, Moayyedi P. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. Curr Gastroenterol Rep 2019;21:65. [PMID: 31807948 DOI: 10.1007/s11894-019-0732-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
256 Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2021. [PMID: 34807007 DOI: 10.14309/ajg.0000000000001538] [Reference Citation Analysis]
257 Chrysant SG, Chrysant GS. Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia. Expert Opin Drug Saf 2020;19:59-67. [PMID: 31795777 DOI: 10.1080/14740338.2020.1700228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Laird J. Magnetic sphincter augmentation device placement for treatment of gastroesophageal reflux. JAAPA 2020;33:30-2. [PMID: 33234893 DOI: 10.1097/01.JAA.0000721664.47053.0e] [Reference Citation Analysis]
259 Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol 2020;13:1756284820913743. [PMID: 32218806 DOI: 10.1177/1756284820913743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
260 Lin M, Zhang S, Zhang M, Shi J, Zhang C, Luo R, You J, Sun J, Zhang J, Gao F. Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23103. [PMID: 33235070 DOI: 10.1097/MD.0000000000023103] [Reference Citation Analysis]
261 Xu Y, Zhang C. Letter to the Editor: Acid Reflux or Non-acid Reflux? Dig Dis Sci 2018;63:3518-9. [DOI: 10.1007/s10620-018-5293-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Devraj R, Deshpande M. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population. Research in Social and Administrative Pharmacy 2020;16:776-82. [DOI: 10.1016/j.sapharm.2019.08.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
263 Fusaro M, D'Arrigo G, Pitino A, Iervasi G, Tentori F, Robinson B, Aghi A, Bieber B, Mccullogh K, Fabris F, Plebani M, Giannini S, Gallieni M, Tripepi G. Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Bone Miner Res 2019;34:2238-45. [PMID: 31365145 DOI: 10.1002/jbmr.3842] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
264 Feng S, Qiu G, Yang L, Feng L, Fan X, Ren F, Huang K, Chen Y. Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation. Biosci Rep 2021;41:BSR20200842. [PMID: 33393595 DOI: 10.1042/BSR20200842] [Reference Citation Analysis]
265 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
266 Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology. 2018;154:302-318. [PMID: 28827081 DOI: 10.1053/j.gastro.2017.07.049] [Cited by in Crossref: 109] [Cited by in F6Publishing: 75] [Article Influence: 21.8] [Reference Citation Analysis]
267 Triadafilopoulos G, Clarke J, Hawn M. Whole greater than the parts: integrated esophageal centers (IEC) and advanced training in esophageal diseases. Dis Esophagus 2017;30:1-9. [PMID: 28859396 DOI: 10.1093/dote/dox084] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
268 Wahking RA, Steele RL, Hanners RE, Lockwood SM, Davis KW. Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution. Hosp Pharm 2018;53:59-67. [PMID: 29434389 DOI: 10.1177/0018578717747192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
269 Odenthal DR, Philbrick AM, Harris IM. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic. J Am Pharm Assoc (2003) 2020;60:100-4. [PMID: 31601478 DOI: 10.1016/j.japh.2019.08.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
270 van Orten-Luiten ACB, Janse A, Verspoor E, Brouwer-Brolsma EM, Witkamp RF. Drug use is associated with lower plasma magnesium levels in geriatric outpatients; possible clinical relevance. Clin Nutr 2019;38:2668-76. [PMID: 30581015 DOI: 10.1016/j.clnu.2018.11.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
271 Boucherie Q, Rouby F, Frankel D, Roll P, Micallef J. Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. Therapie 2018;73:385-8. [PMID: 29778306 DOI: 10.1016/j.therap.2018.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
272 Rameau A, Lee M, Andreadis K, Sulica L. Perception of Proton Pump Inhibitor Side Effects Among Members of the American Broncho-Esophagological Association. J Voice 2021:S0892-1997(21)00173-9. [PMID: 34154915 DOI: 10.1016/j.jvoice.2021.05.006] [Reference Citation Analysis]
273 Zheng YM, Chen XY, Cai JY, Yuan Y, Xie WR, Xu JT, Xia HHX, Zhang M, He XX, Wu LH. Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease. World J Gastroenterol 2021; 27(6): 513-522 [PMID: 33642825 DOI: 10.3748/wjg.v27.i6.513] [Reference Citation Analysis]
274 Paik JM, Rosen HN, Gordon CM, Curhan GC. Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women. Calcif Tissue Int 2018;103:380-7. [PMID: 29754277 DOI: 10.1007/s00223-018-0432-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
275 Zhang Y, Yang H, Kong J, Liu L, Ran L, Zhang X, Yun J, Gu Q. Impact of interventions targeting the inappropriate use of proton-pump inhibitors by clinical pharmacists in a hepatobiliary surgery department. J Clin Pharm Ther 2021;46:149-57. [PMID: 33015848 DOI: 10.1111/jcpt.13273] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 Mohn ES, Kern HJ, Saltzman E, Mitmesser SH, McKay DL. Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update. Pharmaceutics 2018;10:E36. [PMID: 29558445 DOI: 10.3390/pharmaceutics10010036] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
277 Bayram D, Aydin V, Sanli A, Abanoz MN, Sibic B, Pala S, Atac O, Akici A. Comparison of paracetamol and diclofenac prescribing preferences for adults in primary care. Prim Health Care Res Dev 2021;22:e78. [PMID: 34852871 DOI: 10.1017/S1463423621000797] [Reference Citation Analysis]
278 Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, Corley DA. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol 2020;115:706-15. [DOI: 10.14309/ajg.0000000000000591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
279 Vinnakota RD, Brett AS. Iron Deficiency Anemia Associated With Acid-Modifying Medications: Two Cases and Literature Review. Am J Med Sci 2019;357:160-3. [PMID: 30528320 DOI: 10.1016/j.amjms.2018.10.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
280 Pasman EA, Ong B, Witmer CP, Nylund CM. Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly. Curr Allergy Asthma Rep 2020;20:39. [PMID: 32524278 DOI: 10.1007/s11882-020-00926-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
281 Yadav R, Bolia R, Bhat NK. Inappropriate Prescribing of Proton Pump Inhibitors in Children: Insights from a Survey. Indian J Pediatr 2021;88:1055. [PMID: 34196932 DOI: 10.1007/s12098-021-03854-x] [Reference Citation Analysis]
282 Ruffner MA, Juste L, Muir AB. Medical Management of Eosinophilic Esophagitis in Pediatric Patients. Pediatr Clin North Am 2021;68:1191-204. [PMID: 34736584 DOI: 10.1016/j.pcl.2021.07.014] [Reference Citation Analysis]
283 Fisher L, Fisher A, Smith PN. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). J Clin Med 2020;9:E3253. [PMID: 33053671 DOI: 10.3390/jcm9103253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Halpern LR, Adams DR. Medically Complex Dental Implant Patients: Controversies About Systemic Disease and Dental Implant Success/Survival. Dent Clin North Am 2021;65:1-19. [PMID: 33213704 DOI: 10.1016/j.cden.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
285 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
286 Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus 2021;13:e12759. [PMID: 33614352 DOI: 10.7759/cureus.12759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
287 Duncan DR, Larson K, Davidson K, Williams N, Liu E, Watters K, Rahbar R, Rosen RL. Acid Suppression Does Not Improve Laryngomalacia Outcomes but Treatment for Oropharyngeal Dysphagia Might Be Protective. J Pediatr 2021:S0022-3476(21)00633-8. [PMID: 34186104 DOI: 10.1016/j.jpeds.2021.06.051] [Reference Citation Analysis]
288 Moussalem C, Ftouni L, Abou Mrad Z, Bsat S, Houshiemy M, Alomari S, Omeis I. Negative pharmacological effect on spine fusion: A narrative review of the literature of evidence-based treatment. Clin Neurol Neurosurg 2021;207:106799. [PMID: 34304068 DOI: 10.1016/j.clineuro.2021.106799] [Reference Citation Analysis]
289 Kose E, Wakabayashi H, Yasuno N. Polypharmacy and Malnutrition Management of Elderly Perioperative Patients with Cancer: A Systematic Review. Nutrients 2021;13:1961. [PMID: 34200493 DOI: 10.3390/nu13061961] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
290 Dhar A, Maw F, Dallal HJ, Attwood S. Side effects of drug treatments for gastro-oesophageal reflux disease: current controversies. Frontline Gastroenterol 2022;13:45-9. [PMID: 34966532 DOI: 10.1136/flgastro-2019-101386] [Reference Citation Analysis]
291 Sugiyama T. Vitamin D and bone health: interpreting observational studies. J Intern Med 2017;282:272-3. [DOI: 10.1111/joim.12639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
292 Thompson W, Nissen M, Haastrup P, Le JV, Lundby C, Nielsen JB, Jarbøl DE. Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients. BMC Fam Pract 2020;21:160. [PMID: 32770959 DOI: 10.1186/s12875-020-01227-5] [Reference Citation Analysis]
293 Chowdhry M, Shah K, Kemper S, Zekan D, Carter W, Mcjunkin B. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use: PPIs are not associated with hypomagnesemia. Journal of Gastroenterology and Hepatology 2018;33:1717-21. [DOI: 10.1111/jgh.14141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
294 Ishimura N, Sumi S, Okada M, Izumi D, Mikami H, Okimoto E, Ishikawa N, Tamagawa Y, Mishiro T, Oshima N, Shibagaki K, Ishihara S, Maruyama R, Kinoshita Y. Ankylosaurus back sign: novel endoscopic finding in esophageal eosinophilia patients indicating proton pump inhibitor response. Endosc Int Open 2018;6:E165-72. [PMID: 29399613 DOI: 10.1055/s-0043-122882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
295 Bashaw H, Schwartz S, Kagalwalla AF, Wechsler JB. Tutorial: Nutrition Therapy in Eosinophilic Esophagitis—Outcomes and Deficiencies. Journal of Parenteral and Enteral Nutrition 2020;44:600-9. [DOI: 10.1002/jpen.1738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
296 Yadlapati R, Kahrilas PJ. The "dangers" of chronic proton pump inhibitor use. J Allergy Clin Immunol 2018;141:79-81. [PMID: 28729001 DOI: 10.1016/j.jaci.2017.06.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
297 Sebastián Domingo JJ. Proton pump inhibitors in the COVID-19 pandemic. Gastroenterol Hepatol 2021:S0210-5705(21)00166-7. [PMID: 34051314 DOI: 10.1016/j.gastrohep.2021.04.008] [Reference Citation Analysis]
298 Peiffer-Smadja N, Bauvois A, Chilles M, Gramont B, Maatoug R, Bismut M, Thorey C, Oziol E, Hanslik T. The French Society of Internal Medicine's Top-5 List of Recommendations: a National Web-Based Survey. J Gen Intern Med 2019;34:1475-85. [PMID: 31190258 DOI: 10.1007/s11606-019-05050-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
299 Godwin B, Liacouras C, Mehta V, Eisenberg J, Agawu A, Brown-Whitehorn T, Ruffner MA, Verma R, Cianferoni A, Spergel JM, Muir AB. A Review of Tertiary Referrals for Management of Pediatric Esophageal Eosinophilia. Front Pediatr 2018;6:173. [PMID: 29974044 DOI: 10.3389/fped.2018.00173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]